4.6 Review

Arginine regulation by myeloid derived suppressor cells and tolerance in cancer: mechanisms and therapeutic perspectives

Journal

IMMUNOLOGICAL REVIEWS
Volume 222, Issue -, Pages 180-191

Publisher

WILEY
DOI: 10.1111/j.1600-065X.2008.00608.x

Keywords

arginase; myeloid derived suppressor cells; T-cell function

Categories

Funding

  1. NCI NIH HHS [5R01CA107974, 5R01CA082689, R01 CA107974, R01 CA082689] Funding Source: Medline
  2. NCRR NIH HHS [5P20RR021970, P20 RR021970] Funding Source: Medline
  3. NATIONAL CANCER INSTITUTE [R01CA082689, R01CA107974] Funding Source: NIH RePORTER
  4. NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR021970] Funding Source: NIH RePORTER

Ask authors/readers for more resources

Patients with cancer have an impaired T-cell response that can decrease the potential therapeutic benefit of cancer vaccines and other forms of immunotherapy. L-arginine (L-Arg) is a conditionally essential amino acid that is fundamental for the function of T lymphocytes. Recent findings in tumor-bearing mice and cancer patients indicate that increased metabolism of L-Arg by myeloid derived suppressor cells (MDSCs) producing arginase I inhibits T-lymphocyte responses. Here we discuss some of the most recent concepts how MDSC expressing arginase I may regulate T-cell function in cancer and other chronic inflammatory diseases and suggest possible therapeutic interventions to overcome this inhibitory effect.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available